首页 > 文章详情

鼻咽癌的化疗时机

2018年11月17日

编译：肿瘤资讯

来源：肿瘤资讯

鼻咽癌的化疗时机

Joseph Tien Seng Wee

教授

新加坡国立癌症中心放疗科
杜克-新加坡国立大学医学院

随着近年来有关鼻咽癌的临床试验和荟萃分析所展示出来的结果，有人可能会认为诱导化疗是鼻咽癌治疗的新标准方案。但是有两点需要引起我们的注意—诱导化疗后所导致的肿瘤细胞加速再增值和血液学毒性。而对于辅助化疗，最主要的问题就是它的耐受性，因此，我们需要找到新的辅助化疗药物和方案。同时，同期化疗的作用也应该被进一步探索，特别是在早期患者中。鼻咽癌似乎和种族相关，关于鼻咽癌起源人群的“百越假说”，最新的研究发现鼻咽癌起源人群可以追溯到美洲、地中海和阿拉伯海湾地区。

Nasopharyngeal carcinoma: Timing of chemotherapy

With recent results from clinical trials and meta-analysis, one might be tempted to think that induction chemotherapy is the new standard of care for nasopharyngeal carcinoma (NPC). However, two caveats remain – accelerated repopulation and hematological toxicities after induction chemotherapy. With regard to adjuvant chemotherapy, the main issue remains tolerability, and new strategies and new drugs need to be found. The role of concurrent CCRT alone will also be explored especially in the earlier stages. NPC appears to be related to ethnicity, and an update on the Bai-Yue hypothesis tracing NPC to the Americas, the Mediterranean, and the Arabian Gulf will also be presented.